# JAMDA

Original Study

# The Association of Oral Bisphosphonate Use With Mortality Risk Following a Major Osteoporotic Fracture in the United Kingdom: Population-Based Cohort Study

Check for updates

Shahab Abtahi MD [a,b,c,d], Andrea M. Burden PhD [a,c,d,e], Piet Geusens PhD [c],
Joop P. van den Bergh PhD [f,g,h,i], Tjeerd van Staa PhD [d,j], Frank de Vries PhD [a,b,d,k,*]

[a] Department of Clinical Pharmacy and Toxicology, Maastricht University Medical Center+, Maastricht, the Netherlands
[b] Cardiovascular Research Institute Maastricht (CARIM), Maastricht University, Maastricht, the Netherlands
[c] Care and Public Health Research Institute (CAPHRI), Maastricht University, Maastricht, the Netherlands
[d] Division of Pharmacoepidemiology and Clinical Pharmacology, Utrecht Institute for Pharmaceutical Sciences, Utrecht University, Utrecht, the Netherlands
[e] Institute of Pharmaceutical Sciences, Department of Chemistry and Applied Biosciences, ETH Zurich, Zurich, Switzerland
[f] NUTRIM School for Nutrition and Translational Research in Metabolism, Maastricht University, Maastricht, the Netherlands
[g] Division of Rheumatology, Department of Internal Medicine, Maastricht University Medical Center+, Maastricht, the Netherlands
[h] Department of Internal Medicine, VieCuri Medical Center, Venlo, the Netherlands
[i] Faculty of Medicine and Life Sciences, Hasselt University, Hasselt, Belgium
[j] Division of Informatics, Imaging and Data Science, Center for Health Informatics, School of Health Sciences, Faculty of Biology, Medicine and Health, University of Manchester, Manchester Academic Health Science Center, Manchester, United Kingdom
[k] MRC Epidemiology Lifecourse Unit, Southampton General Hospital, Southampton, United Kingdom

## ABSTRACT

*Objectives:* Bisphosphonates (BPs) might have extra benefits in reducing mortality because of their anti-atherosclerotic effects, but studies reported conflicting results. We investigated the association between oral BP use and mortality risk following a major osteoporotic fracture (MOF) in the United Kingdom.
*Design:* This was a population-based cohort study.
*Setting and Participants:* In total, 163,273 adults aged 50 years and older with an MOF between 2000 and 2018 from the Clinical Practice Research Datalink in the United Kingdom.
*Methods:* Cox proportional hazards models were used to estimate the risk of all-cause mortality in current (0–6 months), recent (7–12 months), and past (>1 year) exposures to oral BPs after nonhip MOF and hip fracture. In addition, stratification by sex, BP type, and duration of follow-up was performed.
*Results:* Compared with never users of oral BPs, current BP use was associated with a 7% higher all-cause mortality risk after nonhip MOF, whereas a 28% lower all-cause mortality risk was observed after hip fracture. Past BP exposure was associated with a 14% and 42% lower risk after nonhip MOF and hip fracture, respectively. When considering only the first 5 years of follow-up, mortality risk associated with current BP use was significantly lower for both fracture groups, and the greatest reduction in mortality risk was observed within the first year. Women had slightly lower risk compared with men.

*Conclusions and Implications:* We found a slight increased risk of all-cause mortality with current BP exposure after a nonhip MOF; however, a protective effect was observed following a hip fracture. Both the timing and the effect size of an association based on the anti-atherosclerotic hypothesis of BPs are not supported by our results. The decreasing trend of the mortality risk with shorter durations of follow-up suggests that the observed association is likely due to unknown distortion or unknown pleiotropic properties of BPs.

© 2019 AMDA − The Society for Post-Acute and Long-Term Care Medicine.

Major osteoporotic fractures (MOFs) are the main consequence of osteoporosis, with devastating results for the affected patients, including a significant increased risk of mortality.[1] Occurrence of a hip fracture markedly increases the risk of subsequent fractures (relative risks of 2–7 compared with the general population).[2,3] This may increase mortality after fracture even more.[4] Approximately 33% of men and 22% of women suffering a hip fracture will die within 1 year, and 51% of men and 39% of women sustaining an MOF will die within 5 years.[5–7] But the reasons of this high mortality risk and the ways to prevent it are still not fully understood.

Secondary fracture prevention with anti-osteoporotic treatment, such as bisphosphonates (BPs), can prevent subsequent fractures.[8,9] Given the strong association between fracture and mortality in older individuals, it has been hypothesized that use of BPs may lower the risk of mortality after a fracture. Apart from preventing secondary fractures, the main underlying potential mechanism that could explain the mortality-reducing benefits of BPs is protection against cardiovascular events. This may mostly be the result of lowering lipid profile and decreasing arterial wall calcification.[10–14] However, data from randomized clinical trials (RCTs) yield conflicting evidence.[15,16] Although a post-hoc analysis of the Health Outcomes and Reduced Incidence with Zoledronic Acid Once Yearly (HORIZON) trial showed a 28% statistically significant mortality reduction among users of zoledronic acid after hip fracture,[15] the design, analysis, and conduct of this study have been heavily criticized.[17]

Because the underlying mechanism for mortality reduction is likely similar for various BPs, we sought to further test the hypothesis of an association between all-cause mortality and the initiation of oral BPs following an MOF in a large representative real-life cohort study. Thus, the aim of this study was to examine if oral BP treatment was associated with a lower all-cause mortality risk after a nonhip MOF or hip fracture.

## Methods

### Data Source

This was a cohort study using the Clinical Practice Research Datalink (CPRD; www.cprd.com). The CPRD contains medical records of 674 practices in the United Kingdom representing approximately 6.9% of the total population.[18] Recorded data includes patient demographics, lifestyle parameters, medical history, laboratory test results, prescription details, specialist referrals, hospital admissions, and major outcomes since 1987. Previous studies showed a high validity of using CPRD data regarding MOF.[19]

### Study Population

The study population included all patients aged 50 years and older with a record of their first fracture between January 1, 2000 and December 31, 2018. The index date (start of study follow-up) was defined as the date of first recorded MOF (ie, a fracture of the hip/femur, vertebrae, humerus, or radius/ulna). We further classified fractures by hip or nonhip MOF (ie, vertebrae, humerus, radius/ulna, or femur excluding hip). Patients with any fracture prior to age 50 years and those with use of oral BPs prior to the index date were excluded (adhering to new-user design). Also, to allow for at least 1 year of follow-up, we excluded those with an index fracture in 2018.

### Exposure and Outcome

The exposure of interest was the use of oral BPs after index date, which was assessed time-dependently. First, the total follow-up time for each patient was established by considering the time he/she had entered the study (ie, index date) and the time follow-up ends, which could be the end of study period, the date of transfer out of the practice area, or death (the outcome of interest), whichever came first. The total follow-up time was then divided into 180-day "periods" starting from the index date. Exposure status to BPs was defined as the following: "current exposure" means that the patient has received his most recent BP prescription during the past 6 months before the start of a period. "Recent exposure" means that the patient has taken his most recent BP prescription 7–12 months before, and "past exposure" means that the patient has stopped taking BPs for >1 year before. Using this model, patient exposure is then classified in a dynamic time-dependent manner, meaning they can move between exposure groups (current, recent, past) throughout time. However, once a patient is classified as a current user, he cannot return to the never user group. The total person-time in each category is accounted for and contributes to the Cox proportional hazards model. In addition, BP use was broken down into nitrogen-containing BPs (n-BP, alendronate, and risedronate) and the non-nitrogen-containing BP (non-n-BP) etidronate. The outcome of interest was all-cause mortality as recorded in the CPRD.

### Potential Confounders

Age was considered time dependently, whereas sex, smoking status, alcohol use, and body mass index were determined at index date. A history of the following comorbidities was assessed at the start of each interval: cerebrovascular disease, chronic kidney disease, chronic obstructive pulmonary disease, dementia, diabetes mellitus, epilepsy, heart failure, ischemic heart disease, major infections (sepsis, meningitis, upper and lower respiratory tract infections), or malignant neoplasms (excluding nonmelanoma skin cancers). In addition, the use of following medications in the 6 months prior was included: antihypertensives, anti-Parkinson's medications, glucocorticoids, loop diuretics, psychotropic drugs (antipsychotics, anxiolytics, hypnotics, and sedatives), and statins. Confounders were included in the final model if they changed the beta coefficient of the association >5% or based on expert opinion. Collinearity between potential confounders was assessed.

### Statistical Analysis

Cox proportional hazards models were used to assess the risk of all-cause mortality following fracture associated with current BP use vs never use (using the SAS PHREG procedure). To avoid immortal

time bias, all patient time in each exposure status was incorporated into the model and all patient time prior to first BP use was defined as never use. Analyses were stratified by index fracture type (nonhip MOF vs hip) and sex.

In secondary analyses, current BP exposure was stratified by type of oral BP (n-BP or non-n-BP). A sensitivity analysis assessed 1-year and 5-year all-cause mortality risk, censoring the total follow-up period at 1 or 5 years, respectively.

Data were analyzed using SAS v 9.3 (SAS Institute Inc, Cary, NC).

## Results

A total of 163,273 patients were included in our cohort with a first MOF between 2000 and 2018 (Figure 1). Of the eligible fractures, 119,107 (72.9%) were nonhip MOF and 44,166 (27.1%) were fractures (Table 1). The mean age of patients with a nonhip MOF and hip fracture were 70 and 81 years, respectively. Female patients accounted for 74% of the nonhip MOF and 69% of hip fracture patients. A similar pattern of smoking was observed among both fracture groups, with less than one quarter of patients being current smokers. Frequent comorbidity and comedication included major infections and anti-hypertensives. The nonhip MOF comprised 16,378 vertebral fractures (13.8%), 5294 femur fractures (4.4%), 33,665 humerus fractures (28.3%), and 63,770 radius/ulna fractures (53.5%). The follow-up time for BP users was 7.6 years in the nonhip MOF and 5.7 years in the hip fracture group. The average duration of BP use was 3.3 years among nonhip MOF patients and 2.7 years among hip fracture patients.

Table 2 shows that current use of oral BPs was associated with a 7% higher risk of all-cause mortality among patients with an index non-hip MOF compared with never use (adjusted hazard ratio [$HR_{adj}$] 1.07, 95% confidence interval [CI] 1.03–1.10). Mortality risk in the recent exposure group was also higher compared with the reference group ($HR_{adj}$ 1.25, 95% CI 1.16–1.36), but past exposure was associated with statistically significant lower risk ($HR_{adj}$ 0.86, 95% CI 0.83–0.90). Among patients who had sustained a hip fracture, current BP exposure was associated with a significant 28% lower mortality risk compared with never BP exposure ($HR_{adj}$ 0.72, 95% CI 0.70–0.75), whereas recent and past exposures were associated with 21% and 42% lower risk, respectively. The HR of past exposure was statistically lower compared

with recent and current exposure. In general, mortality risk tended to be slightly lower among women as compared with men.

Stratifying our analysis by nitrogen-containing BPs showed similar results to the primary analysis. Analyses with the non-n-BP etidronate lacked statistical power due to low frequency of exposure (data not shown).

The 5-year analysis showed a significant reduction in mortality risk with current BP exposure after nonhip MOF ($HR_{adj}$ 0.91, 95% CI 0.87–0.95) compared with never use (Table 3). Following a hip fracture, all-cause mortality risk associated with current exposure shifted further from the null value with a significant 39% reduction compared to never use ($HR_{adj}$ 0.61, 95% CI 0.59–0.64).

The 1-year mortality risk (data not shown) in the nonhip MOF group showed a 34% lower risk of all-cause mortality with current BP exposure ($HR_{adj}$ 0.66, 95% CI 0.60–0.72), whereas it was not lower with recent exposure ($HR_{adj}$ 0.23, 95% CI 0.03–1.61). The 1-year risk of all-cause mortality among hip fracture patients was considerably lower for current BP exposure ($HR_{adj}$ 0.41, 95% CI 0.37–0.44), but not for recent ($HR_{adj}$ 0.79, 95% CI 0.33–1.90).

## Discussion

This study identified that current oral BP exposure was associated with a 7% higher all-cause mortality risk after a nonhip MOF and with a 28% lower mortality risk after a hip fracture. When the follow-up time was censored at 1 and 5 years, a significant protective effect was observed in both fracture groups, with a trend away from the null with decreasing follow-up time: mortality risk with current BP use in the nonhip MOF group first dropped to a 9% reduction in the 5-year and then to 34% reduction in the 1-year analysis. In the case of hip fracture, mortality risk with current BP use first dropped to a 39% reduction in the 5-year and then to 59% in the 1-year analysis.

Our finding of a higher mortality risk among nonhip MOF patients with current BP exposure is not in line with findings from 2 meta-analyses of RCTs in 2010 (n = 25,072) and 2018 (n = 63,371), which showed no association between all-cause mortality and BP use vs placebo, yielding a pooled relative risk of 0.91 (95% CI 0.80–1.03) and 0.95 (95% CI 0.86–1.04), respectively.[20,21] However, the 28% lower mortality risk after hip fracture with current BP exposure in our study could be in line with those from the HORIZON trial, which showed a 28% reduced risk of all-cause mortality after 16 months of zoledronic acid use (HR 0.72; 95% CI 0.56–0.93), and was included in both meta-analyses.[15] However, RCTs have normally evaluated BP use in individual patients in a time-fixed model, while we assessed person-time within exposure states in a time-dependent analysis.

Our results in patients with hip fractures are in line with those from other observational studies in the field. In a recent cohort study by van Geel et al, a 21% reduction in mortality risk (HR 0.79, 95% CI 0.64–0.97) was reported with oral BP use compared to calcium and vitamin D use among fracture patients.[22] Using Danish national health register data, Bondo et al observed survival benefits for patients who had taken BP both before and after hip fracture, although their results may be distorted due to channelling or immortal time bias.[23] Sambrook et al found 27% mortality reduction for oral BP use compared to no use in frail older people (mean age = 86 years), and an even higher reduction (80%) in those only after hip fracture, although the number of BP users were very low (n = 17).[24,25]

However, BPs are not always found in literature to be beneficial on mortality risk reduction. Steinbuch et al reported no significant risk reduction in all-cause mortality for risedronate in patients with a history of vertebral or hip fracture or with low bone mass, although there was some benefits in case of stroke and cardiovascular events reduction.[14] In "primary prevention arm" of the HORIZON trial, Black et al reported a small but not statistically significant increase in death



**Fig. 1.** Flowchart on establishment of patient population. All patients aged over 50 years from the CPRD in the UK who had a major osteoporotic fracture between 2000 and 2018, and started bisphosphonate use after the (index, first) fracture are included in the study. *50+ patients*, patients aged over 50 years; UTS, up to standard time of the CPRD practice.

**Table 1**
Baseline Characteristics of Participants According to Index Fracture Site

| | Nonhip MOF | | Hip Fracture | |
|---|---|---|---|---|
| | n | % - SD | n | % - SD |
| Number of events | 119,107 | | 44,166 | |
| Follow-up time (y) | 6.7 | 4.8 | 3.9 | 4.0 |
| Mean age, y | 70.1 | 11.9 | 80.5 | 10.3 |
| Female | 88,415 | 74.2 | 30,645 | 69.4 |
| Mean BMI | 26.6 | 5.5 | 24.3 | 4.9 |
| Smoking status | | | | |
| Never | 70,241 | 59.0 | 25,593 | 57.9 |
| Past | 17,856 | 15.0 | 6878 | 15.6 |
| Current | 29,056 | 24.4 | 9443 | 21.4 |
| Missing | 1954 | 1.6 | 2252 | 5.1 |
| Alcohol use | | | | |
| Yes | 80,188 | 67.3 | 22,786 | 51.6 |
| No | 28,937 | 24.3 | 13,921 | 31.5 |
| Missing | 9982 | 8.4 | 7459 | 16.9 |
| Comorbidities* | | | | |
| Cerebrovascular disease | 10,825 | 9.1 | 7908 | 17.9 |
| Chronic kidney disease | 11,168 | 9.4 | 7850 | 17.8 |
| COPD | 8269 | 6.9 | 4198 | 9.5 |
| Dementia | 4395 | 3.7 | 6142 | 13.9 |
| Diabetes mellitus | 12,820 | 10.8 | 6247 | 14.1 |
| Epilepsy | 3630 | 3.0 | 1520 | 3.4 |
| Heart failure | 3284 | 2.8 | 2626 | 5.9 |
| IHD | 15,268 | 12.8 | 8218 | 18.6 |
| Major infection | 31,928 | 26.8 | 10,660 | 24.1 |
| Malignant neoplasm | 14,816 | 12.4 | 7568 | 17.1 |
| Prior fracture | 0 | 0.0 | 0 | 0.0 |
| Medications† | | | | |
| Antihypertensives‡ | 49,832 | 41.8 | 22,195 | 50.3 |
| Anti-Parkinson's | 1428 | 1.2 | 1325 | 3.0 |
| BP history | 0 | 0.0 | 0 | 0.0 |
| Loop diuretics | 13,933 | 11.7 | 9790 | 22.2 |
| Glucocorticoids | 5944 | 5.0 | 2325 | 5.3 |
| Psychotropics | 16,299 | 13.7 | 9580 | 21.7 |
| Statins | 30,354 | 25.5 | 11,820 | 26.8 |
| Fracture at baseline | | | | |
| Hip | n/a | n/a | 44,166 | 100 |
| Vertebral | 16,378 | 13.8 | n/a | n/a |
| Femur | 5294 | 4.4 | n/a | n/a |
| Humerus | 33,665 | 28.3 | n/a | n/a |
| Radius/ulna | 63,770 | 53.5 | n/a | n/a |

BMI, body mass index; COPD, chronic obstructive pulmonary disease; IHD, ischemic heart disease; SD, standard deviation.

*Disease comorbidities happened ever before.

†Medications taken 6 months before index fracture.

‡Excluding loop diuretics.

numbers by using zoledronic acid and raised risk of serious atrial-fibrillation adverse events.[16] This might be comparable with our findings regarding the 7% higher mortality risk with current BP use in nonhip MOF patients. Although similar results regarding atrial-fibrillation events have been reported from the Fracture Intervention Trial by using alendronate, this unconfirmed association has no apparent biologic plausibility, and we do not expect this happening to our patients.[26]

There is some evidence from the literature regarding the anti-atherosclerotic effects of BPs, such as lowering low-density lipopro-tein (LDL) cholesterol levels, decreasing arterial wall calcification, enhancing endothelial nitric oxide production, and reducing mono-cytes and platelets interactions with epithelial cells.[12,13,27–30] If car-diovascular effects of BPs would be comparable to those of statins, there should be (indirect) evidence of comparability of the timing and size of the effect. Large RCTs showed that the statin-induced reductions of mortality occurred after 11–24 months of use, which suggests that the mortality reduction starting after 16 months of BP use in the HORIZON trial may be plausible.[31–34] If we assume this timing to be true, part of our observations, such as the lower mortality

among hip fracture patients (with 2.7 years of BP use) might be in line with the explained anti-atherosclerotic hypothesis of BPs. However, even among hip fracture patients, we observed the lowest mortality risk within 1-year analysis, which does not support this hypothesis as the proper timing has not been met. Also, the expected effect size is not comparable: large meta-analyses of RCTs comparing statin use with placebo reported an overall 13% reduction of all-cause mortality, or 9% mortality reduction per 1.0 mmol/L reduction of LDL choles-terol.[35,36] BPs have been shown to lower LDL in a range from no effect up to a reduction of approximately 0.34 mmol/L, after 6–12 months of use.[12,37,38] In the best-case scenario, this would then translate into a 3% lower risk of all-cause mortality,[36] which is around 9 times lower than the observed 28% reduction in the HORIZON trial and results of our study in the hip fracture patients.[15] Nevertheless, BPs could have other anti-atherosclerotic effects. A meta-analysis showed BPs have decreased aortic calcification by 11.2% compared with untreated in-dividuals,[13] and coronary artery calcification is a well-known risk factor for all-cause mortality.[39,40]

Although some causal effect of BPs on all-cause mortality cannot be excluded, it is more likely that unmeasured distortion explains the largest proportion of the observed risk reductions in the HORIZON trial and our study. The HORIZON trial was later criticized because of some inconsistencies regarding the interpretation of data, early termination of the trial, and the high number of withdrawal or loss to follow-up.[17] Observational studies may have been confounded by se-lective prescribing of BPs to patients at lower risk of mortality.[41] Physicians rarely prescribe oral BPs to very ill and hospitalized pa-tients. This can culminate in a spurious survival benefit for exposure drug as the very ill patients are unlikely to receive preventative medication. Moreover, healthy user and healthy adherer bias could also play a role.[42,43] Previous studies have suggested that patients who start a preventative medication or who are more adherent are generally healthier than patients who are not, and therefore may be at lower risk of mortality.[44] These bias scenarios, in addition to the high mortality rates in the early days after a fracture, could best explain the lowest HRs with 1-year analysis and the observed decreasing trend of HRs with shorter durations of follow-up. Moreover, assuming these bias scenarios, the generally lower HRs among the hip fracture pa-tients, compared with the nonhip MOF patients, could be partly explained by longer hospitalization and higher mortality rates after a hip fracture compared with other MOFs.[45] Hip fracture patients are generally sicker with higher chance of mortality and, hence, are less likely to receive BPs.

Our study had several strengths. First, we used the CPRD for data collection, which is one of the world's largest primary care databases. Second, as our study period was relatively long (ie, 19 years [2000-2018]), we could include more than 163,000 patients in the study cohort, which is by far the largest study sample among observational studies in this topic. Also, we considered not only hip but all MOFs, making this the first study to our knowledge to evaluate the mor-tality after nonhip MOF with BP use. Furthermore, the statistical analysis was performed time-dependently, which means it incorpo-rated all person time, avoiding immortal time bias.[46] Moreover, we used different approaches to test the underlying hypothesis of a causal effect,[47] such as assessing the same research question in 2 cohorts with different fracture sites and testing the underlying pharmacologic hypothesis with analyses that evaluated the onset and ending of the effect, which the other observational studies did not do.[14,22–25]

This study had also some limitations. One objective was to differ-entiate between n-BP or non-n-BP respecting their effect on mortality reduction, which was not feasible due to low numbers of non-n-BP use in the United Kingdom. As mentioned above, we could not exclude those dying shortly after having a fracture, and this could result in

**Table 2**
Risk of All-Cause Mortality Following an Index Fracture (Nonhip MOF and Hip), Stratified by Fracture Type, Sex, and Oral BP Exposure Status

| | Events | IR per 1000 Pys | Age (/Sex) Adjusted Model HR (95%CI)* | Final Adjusted Model HR (95% CI)[†] |
|---|---|---|---|---|
| **Nonhip MOF** | | | | |
| BP Never exposure[‡] | 21,940 | 34.6 | Reference | Reference |
| BP Past exposure | 2341 | 36.1 | 0.85 (0.81–0.89) | 0.86 (0.83–0.90)[§] |
| BP Recent exposure | 627 | 57.9 | 1.40 (1.30–1.52) | 1.25 (1.16–1.36)[§] |
| BP Current exposure‖ | 5219 | 57.4 | 1.32 (1.28–1.37) | 1.07 (1.03–1.10)[§] |
| Female** | | | | |
| BP Never exposure | 14,535 | 31.4 | Reference | Reference |
| BP Past exposure | 1933 | 33.2 | 0.82 (0.78–0.86) | 0.85 (0.81–0.89)[§] |
| BP Recent exposure | 480 | 50.2 | 1.30 (1.19–1.43) | 1.19 (1.09–1.31)[§] |
| BP Current exposure‖ | 4003 | 50.1 | 1.25 (1.21–1.30) | 1.04 (1.01–1.08)[§] |
| Male** | | | | |
| BP Never exposure | 7405 | 43.2 | Reference | Reference |
| BP Past exposure | 408 | 61.7 | 0.93 (0.84–1.03) | 0.88 (0.80–0.98)[§] |
| BP Recent exposure | 147 | 115.1 | 1.81 (1.53–2.13) | 1.47 (1.25–1.73)[§] |
| BP Current exposure‖ | 1216 | 109.7 | 1.61 (1.52–1.72) | 1.14 (1.07–1.21)[§] |
| **Hip Fracture** | | | | |
| BP Never exposure[‡] | 16,977 | 152.3 | Reference | Reference |
| BP Past exposure | 1440 | 62.5 | 0.51 (0.48–0.53) | 0.58 (0.55–0.62) |
| BP Recent exposure | 398 | 96.2 | 0.75 (0.68–0.83) | 0.79 (0.71–0.87)[††] |
| BP Current exposure‖ | 3778 | 103.5 | 0.76 (0.73–0.78) | 0.72 (0.70–0.75)[††] |
| Female** | | | | |
| BP Never exposure | 10,942 | 145.1 | Reference | Reference |
| BP Past exposure | 1123 | 59.3 | 0.50 (0.47–0.54) | 0.58 (0.54–0.61)[§] |
| BP Recent exposure | 305 | 91.8 | 0.76 (0.68–0.85) | 0.81 (0.72–0.90)[§] |
| BP Current exposure‖ | 2738 | 92.4 | 0.71 (0.68–0.74) | 0.69 (0.66–0.72)[§] |
| Male** | | | | |
| BP Never exposure | 6035 | 167.5 | Reference | Reference |
| BP Past exposure | 317 | 77.0 | 0.49 (0.43–0.55) | 0.58 (0.52–0.65) |
| BP Recent exposure | 93 | 114.5 | 0.69 (0.56–0.85) | 0.73 (0.59–0.89) |
| BP Current exposure‖ | 1040 | 151.2 | 0.87 (0.81–0.93) | 0.80 (0.75–0.85)[††] |

IR, incidence rate; Pys, person years.

*Adjusted only for age where stratified by sex.

[†]Adjusted for sex, body mass index, smoking status and alcohol use at baseline, and the following variables time dependently: age and use of antihypertensives, anti-Parkinson's medications, loop diuretics, glucocorticoids, psychotropics, and statins in the previous 6 months, and history of malignant neoplasm, dementia (for hip fracture group), and chronic obstructive pulmonary disease (for nonhip MOF group).

[‡]Never exposure denotes to no known use of oral BPs, whereas past, recent, and current exposures refer to taking oral BPs in the time window >12 months, 6–12 months, and 0–6 months prior to the start of a period, respectively.

[§]HR from each BP exposure status is statistically different from the other exposure status in the same model, by Wald test, $P < .05$.

‖Not stratified by nitrogen containing agents because of small cell sizes and reporting restrictions in the CPRD for privacy reasons.

**Patients from each sex are compared only with same sex cohorts.

[††]HR is statistically different from the past exposure status, by Wald test, $P < .05$.

distortion (ie, higher estimates of drug effect than what it should be, especially with shorter durations of follow-up). Moreover, we could not measure or adjust for healthy user or healthy adherer effect, and we had no information about the cause of death, socioeconomic status of patients, or other similar indicators from CPRD. Nonetheless, we tried to overcome this by running multiple analyses that tested the same hypothesis indirectly in different ways, taking into account the hypothesized pharmacologic effect.

**Table 3**
Five-Year Risk of All-Cause Mortality Following an Index Fracture (Nonhip MOF and Hip), by Oral BP Exposure Status

| | Events | IR per 1000 Pys | Age/Sex Adjusted Model HR (95% CI) | Final Adjusted Model* HR (95%CI) |
|---|---|---|---|---|
| **Nonhip MOF** | | | | |
| BP Never exposure[†] | 16,162 | 42.5 | Reference | Reference |
| BP Past exposure | 753 | 43.2 | 0.73 (0.68–0.79) | 0.76 (0.70–0.82) |
| BP Recent exposure | 342 | 55.9 | 1.00 (0.90–1.12) | 0.98 (0.88–1.09)[‡] |
| BP Current exposure | 3135 | 56.5 | 1.03 (0.99–1.07) | 0.91 (0.87–0.95)[‡] |
| **Hip Fracture** | | | | |
| BP Never exposure[†] | 14,946 | 183.1 | Reference | Reference |
| BP Past exposure | 644 | 75.7 | 0.43 (0.40–0.47) | 0.50 (0.47–0.55) |
| BP Recent exposure | 279 | 95.7 | 0.56 (0.50–0.64) | 0.62 (0.55–0.70)[‡] |
| BP Current exposure | 2831 | 103.3 | 0.60 (0.58–0.63) | 0.61 (0.59–0.64)[‡] |

IR, incidence rate; Pys, person years.

*Adjusted for sex, body mass index, smoking status and alcohol use at baseline, and the following variables time dependently: age and use of antihypertensives, anti-Parkinson's medications, loop diuretics, glucocorticoids, psychotropics, and statins in the previous 6 months, and history of: malignant neoplasm, dementia (for hip fracture group), and chronic obstructive pulmonary disease (for nonhip MOF group).

[†]Never exposure denotes to no known use of oral bisphosphonates, whereas past, recent, and current exposures refer to taking oral bisphosphonates in the time window >12 months, 6–12 months, and 0–6 months prior to the start of a period, respectively.

[‡]HR is statistically different from the past exposure status, by Wald test, $P < .05$.

## Conclusions and Implications

In conclusion, although we found a higher risk of all-cause mortality with current BP exposure after nonhip MOF, a protective effect was observed with 1 and 5 years of follow-up. After a hip fracture, current BP exposure was associated with lower mortality risk in all analyses. Compared to statin studies and the effect of BPs on LDL reduction or arterial calcification, both the timing and the effect size of such an association is not supported by our results. Rather, the substantially lower mortality risk in the 1-year analysis and the decreasing trend of HRs with shorter durations of follow-up suggest that the vast majority of the observed association between BP use and mortality risk after fracture is explained by unknown distortion or unknown pleiotropic properties of BPs. We recommend that future studies focus on evaluation of these hypotheses to elucidate alternative mechanisms of potential pleiotropic effects of BPs, and on explaining potential unmeasured distortion.

## References

1. Nazrun AS, Tzar MN, Mokhtar SA, Mohamed IN. A systematic review of the outcomes of osteoporotic fracture patients after hospital discharge: Morbidity, subsequent fractures, and mortality. Ther Clin Risk Manag 2014;10:937–948.
2. van der Velde RY, Wyers CE, Geusens PPMM, et al. Incidence of subsequent fractures in the UK between 1990 and 2012 among individuals 50 years or older. Osteoporos Int 2018;29:2469–2475.
3. Gibson-Smith D, Klop C, Elders PJ, et al. The risk of major and any (nonhip) fragility fracture after hip fracture in the United Kingdom: 2000–2010. Osteoporos Int 2014;25:2555–2563.
4. Bliuc D, Nguyen ND, Milch VE, et al. Mortality risk associated with low-trauma osteoporotic fracture and subsequent fracture in men and women. JAMA 2009; 301:513–521.
5. Brauer CA, Coca-Perraillon M, Cutler DM, Rosen AB. Incidence and mortality of hip fractures in the United States. JAMA 2009;302:1573–1579.
6. Bliuc D, Nguyen ND, Nguyen TV, et al. Compound risk of high mortality following osteoporotic fracture and refracture in elderly women and men. J Bone Miner Res 2013;28:2317–2324.
7. Klop C, Welsing PM, Cooper C, et al. Mortality in British hip fracture patients, 2000-2010: A population-based retrospective cohort study. Bone 2014;66: 171–177.
8. Wells G, Cranney A, Peterson J, et al. Risedronate for the primary and secondary prevention of osteoporotic fractures in postmenopausal women. Cochrane Database Syst Rev 2008;1:CD004523.
9. Lee SY, Jung SH, Lee SU, et al. Can bisphosphonates prevent recurrent fragility fractures? A systematic review and meta-analysis of randomized controlled trials. J Am Med Dir Assoc 2018;19:384–390.e1.
10. Colón-Emeric CS, Mesenbrink P, Lyles KW, et al. Potential mediators of the mortality reduction with zoledronic acid after hip fracture. J Bone Miner Res 2010;25:91–97.
11. Ugur Ural A, Avcu F, Ozturk K. Bisphosphonates may retrieve endothelial function in vascular diseases similar to statins' effects. Eur J Haematol 2008;81: 77–78.
12. Guney E, Kisakol G, Ozgen AG, et al. Effects of bisphosphonates on lipid metabolism. Neuro Endocrinol Lett 2008;29:252–255.
13. Kranenburg G, Bartstra JW, Weijmans M, et al. Bisphosphonates for cardiovascular risk reduction: A systematic review and meta-analysis. Atherosclerosis 2016;252:106–115.
14. Steinbuch M, D'Agostino RB, Mandel JS, et al. Assessment of mortality in patients enrolled in a risedronate clinical trial program: A retrospective cohort study. Regul Toxicol Pharmacol 2002;35:320–326.
15. Lyles KW, Colón-Emeric CS, Magaziner JS, et al. Zoledronic acid and clinical fractures and mortality after hip fracture. N Engl J Med 2007;357:1799–1809.
16. Black DM, Delmas PD, Eastell R, et al. Once-yearly zoledronic acid for treatment of postmenopausal osteoporosis. N Engl J Med 2007;356:1809–1822.
17. Järvinen TL, Michaëlsson K, Jokihaara J, et al. Overdiagnosis of bone fragility in the quest to prevent hip fracture. BMJ 2015;350. h2088.
18. Herrett E, Gallagher AM, Bhaskaran K, et al. Data resource profile: Clinical Practice Research Datalink (CPRD). Int J Epidemiol 2015;44:827–836.
19. Van Staa TP, Abenhaim L, Cooper C, et al. The use of a large pharmacoepidemiological database to study exposure to oral corticosteroids and risk of fractures: Validation of study population and results. Pharmacoepidemiol Drug Saf 2000;9:359–366.
20. Bolland MJ, Grey AB, Gamble GD, Reid IR. Effect of osteoporosis treatment on mortality: A meta-analysis. J Clin Endocrinol Metab 2010;95:1174–1181.
21. Cummings SR, Lui LY, Eastell R, Allen IE. Association between drug treatments for patients with osteoporosis and overall mortality rates: A meta-analysis. JAMA Intern Med 2019;179:1491–1500.
22. van Geel TACM, Bliuc D, Geusens PPM, et al. Reduced mortality and subsequent fracture risk associated with oral bisphosphonate recommendation in a fracture liaison service setting: A prospective cohort study. PLoS One 2018;13: e0198006.
23. Bondo L, Eiken P, Abrahamsen B. Analysis of the association between bisphosphonate treatment survival in Danish hip fracture patients-a nationwide register-based open cohort study. Osteoporos Int 2013;24:245–252.
24. Sambrook PN, Cameron ID, Chen JS, et al. Oral bisphosphonates are associated with reduced mortality in frail older people: A prospective five-year study. Osteoporos Int 2011;22:2551–2556.
25. Cameron ID, Chen JS, March LM, et al. Hip fracture causes excess mortality owing to cardiovascular and infectious disease in institutionalized older people: A prospective 5-year study. J Bone Miner Res 2010;25:866–872.
26. Cummings SR, Schwartz AV, Black DM. Alendronate and atrial fibrillation. N Engl J Med 2007;356:1895–1896.
27. Sing CW, Wong AY, Kiel DP, et al. Association of alendronate and risk of cardiovascular events in patients with hip fracture. J Bone Miner Res 2018;33: 1422–1434.
28. Cutini PH, Rauschemberger MB, Sandoval MJ, Massheimer VL. Vascular action of bisphosphonates: In vitro effect of alendronate on the regulation of cellular events involved in vessel pathogenesis. J Mol Cell Cardiol 2016;100:83–92.
29. Okamoto M, Yamanaka S, Yoshimoto W, Shigematsu T. Alendronate as an effective treatment for bone loss and vascular calcification in kidney transplant recipients. J Transplant 2014;2014:269613.
30. Elmariah S, Delaney JA, O'Brien KD, et al. Bisphosphonate use and prevalence of valvular and vascular calcification in women MESA (The Multi-Ethnic Study of Atherosclerosis). J Am Coll Cardiol 2010;56:1752–1759.
31. Scandinavian Simvastatin Survival Study Group. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: The Scandinavian Simvastatin Survival Study (4S). Lancet 1994;344:1383–1389.
32. Heart Protection Study Collaborative Group. MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: A randomised placebo-controlled trial. Lancet 2002;360:7–22.
33. Shepherd J, Cobbe SM, Ford I, et al. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. West of Scotland Coronary Prevention Study Group. N Engl J Med 1995;33:1301–1307.
34. Nakamura H, Arakawa K, Itakura H, et al; MEGA Study Group. Primary prevention of cardiovascular disease with pravastatin in Japan (MEGA Study): A prospective randomised controlled trial. Lancet 2006;368:1155–1163.
35. Naci H, Brugts JJ, Fleurence R, Ades AE. Comparative benefits of statins in the primary and secondary prevention of major coronary events and all-cause mortality: A network meta-analysis of placebo-controlled and active-comparator trials. Eur J Prev Cardiol 2013;20:641–657.
36. Cholesterol Treatment Trialists' (CTT) Collaborators, Mihaylova B, Emberson J, Blackwell L, et al. The effects of lowering LDL cholesterol with statin therapy in people at low risk of vascular disease: Meta-analysis of individual data from 27 randomised trials. Lancet 2012;380:581–590.
37. Gonnelli S, Caffarelli C, Tanzilli L, et al. Effects of intravenous zoledronate and ibandronate on carotid intima-media thickness, lipids and FGF-23 in postmenopausal osteoporotic women. Bone 2014;61:27–32.
38. Celiloglu M, Aydin Y, Balci P, Kolamaz T. The effect of alendronate sodium on carotid artery intima-media thickness and lipid profile in women with postmenopausal osteoporosis. Menopause 2009;16:689–693.
39. Alexopoulos N, Raggi P. Calcification in atherosclerosis. Nat Rev Cardiol 2009;6: 681–688.
40. Taylor AJ, Burke AP, O'Malley PG, et al. A comparison of the Framingham risk index, coronary artery calcification, and culprit plaque morphology in sudden cardiac death. Circulation 2000;101:1243–1248.
41. Shrank WH, Patrick AR, Brookhart MA. Healthy user and related biases in observational studies of preventive interventions: A primer for physicians. J Gen Intern Med 2011;26:546–550.
42. Brookhart MA, Stürmer T, Glynn RJ, et al. Confounding control in healthcare database research: Challenges and potential approaches. Med Care 2010;48: S114–S1120.
43. Devold HM, Furu K, Skurtveit S, et al. Influence of socioeconomic factors on the adherence of alendronate treatment in incident users in Norway. Pharmacoepidemiol Drug Saf 2012;21:297–304.
44. Curtis JR, Delzell E, Chen L, et al. The relationship between bisphosphonate adherence and fracture: Is it the behavior or the medication? Results from the placebo arm of the fracture intervention trial. J Bone Miner Res 2011;26: 683–688.
45. Center JR, Nguyen TV, Schneider D, et al. Mortality after all major types of osteoporotic fracture in men and women: An observational study. Lancet 1999; 353:878–882.
46. Suissa S. Immortal time bias in pharmaco-epidemiology. Am J Epidemiol 2008; 167:492–499.
47. Savitz DA, Wellenius GA. Interpreting Epidemiologic Evidence: Connecting Research to Applications. 2nd ed. Oxford University Press; 2016.